Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

LNX1 Contributes to Cell Cycle Progression and Cisplatin Resistance

Minsu Jang1, Rackhyun Park1, Yea-In Park1

  • 1Division of Biological Science and Technology, Yonsei University, Wonju 26493, Korea.

Cancers
|August 27, 2021
PubMed

Insights

Ligand of numb-protein X1 (LNX1) promotes cell cycle progression and cisplatin resistance. LNX1 expression is regulated by DNA damage and inflammatory stimuli, impacting cell division and survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Ligand of numb-protein X1 (LNX1) functions as a proto-oncogene by inhibiting p53 stability.
  • The regulatory mechanisms governing LNX1 expression remain largely uninvestigated.

Purpose of the Study:

  • To identify factors that regulate LNX1 expression.
  • To elucidate the role of LNX1 in cell-cycle progression and chemoresistance.

Main Methods:

  • Chemical screening to identify LNX1 expression regulators.
  • Treatment with DNA-damaging agents (cisplatin), lipopolysaccharide (LPS), and phorbol 12-myristate 13-acetate (PMA).
  • CRISPR-Cas9 gene editing to create LNX1 knockout cells.
  • Cell-cycle analysis (flow cytometry) and gene expression analysis.

Main Results:

  • LNX1 expression decreased upon DNA damage (cisplatin) and increased with LPS and PMA treatment.
  • LNX1 expression correlated with increased S and G2/M cell-cycle populations.
  • LNX1 knockout cells exhibited delayed cell-cycle progression and downregulated cyclin D1 and cyclin E1.
  • Upregulation of LNX1 enhanced cell-cycle progression and increased resistance to cisplatin-induced cell death.

Conclusions:

  • LNX1 plays a significant role in promoting cell-cycle progression.
  • LNX1 contributes to cellular resistance against cisplatin-mediated apoptosis.
  • LNX1 expression is modulated by DNA damage and inflammatory signals, suggesting its involvement in cancer development and progression.
Keywords:
LNX1cell cyclecell deathcisplatin

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.9K

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K